Exact Mass: 503.107

Exact Mass Matches: 503.107

Found 46 metabolites which its exact mass value is equals to given mass value 503.107, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

AM1241

(2-Iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone

C22H22IN3O3 (503.0706)


   

Pyranodelphinin B

11-hydroxy-3-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-7-(3,4,5-trihydroxyphenyl)-2λ⁴,8-dioxatricyclo[7.3.1.0⁵,¹³]trideca-1,3,5(13),6,9,11-hexaen-2-ylium

C24H23O12 (503.1189)


Pyranodelphinin B is found in fruits. Pyranodelphinin B is a constituent of the seeds of Ribes nigrum (blackcurrant)

   

(2-Iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone

(2-Iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone

C22H22IN3O3 (503.0706)


   

7-(3-((4-Iodophenylsulfonyl)amino)bicyclo(2.2.1)hep-2-yl)-5-heptenoic acid

7-(3-((4-Iodophenylsulphonyl)amino)bicyclo(2.2.1)hep-2-yl)-5-heptenoic acid

C20H26INO4S (503.0627)


   

(Z)-2-((R)-1-((S)-1-(2-Chlorophenyl)-2-methoxy-2-oxoethyl)-4-((2-(3-methoxyphenyl)-2-oxoethyl)thio)piperidin-3-ylidene)acetic acid

(Z)-2-((R)-1-((S)-1-(2-Chlorophenyl)-2-methoxy-2-oxoethyl)-4-((2-(3-methoxyphenyl)-2-oxoethyl)thio)piperidin-3-ylidene)acetic acid

C25H26ClNO6S (503.1169)


   

Sporidesmin D

12-chloro-8,9-dihydroxy-13,14-dimethoxy-4,5,16-trimethyl-4,7-bis(methylsulfanyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-10,12,14-triene-3,6-dione

C20H26ClN3O6S2 (503.0951)


   

Mesosulfuron-methyl

Mesosulfuron-methyl

C17H21N5O9S2 (503.0781)


CONFIDENCE standard compound; EAWAG_UCHEM_ID 3170

   

Antibiotic PA 32413-I

Antibiotic PA 32413-I

C18H25N5O10S (503.1322)


   
   

Sulfuric acid 2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazine-3-yl ester

Sulfuric acid 2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazine-3-yl ester

C26H21N3O6S (503.1151)


   
   
   
   

(R)-AM1241

(2-iodo-5-nitrophenyl)[1-[[(2R)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]methanone

C22H22IN3O3 (503.0706)


   

(S)-AM1241

(2-iodo-5-nitrophenyl)[1-[[(2S)-1-methyl-2-piperidinyl]methyl]-1H-indol-3-yl]-methanone

C22H22IN3O3 (503.0706)


   

Pyranodelphinin B

11-hydroxy-7-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-(3,4,5-trihydroxyphenyl)-2$l^{4},8-dioxatricyclo[7.3.1.0^{5,13}]trideca-1(12),2,4,6,9(13),10-hexaen-2-ylium

C24H23O12 (503.1189)


   

Rosuvastatin calcium

Rosuvastatin calcium

C22H27FN3NaO6S (503.1502)


Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].

   

4-[methyl[(undecafluoropentyl)sulphonyl]amino]butyl methacrylate

4-[methyl[(undecafluoropentyl)sulphonyl]amino]butyl methacrylate

C14H16F11NO4S (503.0624)


   

2 3 5-TRI-O-BENZOYL-BETA-D-RIBOFURANOSYL

2 3 5-TRI-O-BENZOYL-BETA-D-RIBOFURANOSYL

C27H21NO7S (503.1039)


   
   
   

2-Chloro-4-nitrophenyl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside

2-Chloro-4-nitrophenyl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside

C20H22ClNO12 (503.083)


   
   

5-methyltetrahydrofolic acid disodium salt

5-methyltetrahydrofolic acid disodium salt

C20H23N7Na2O6 (503.1505)


   

2-Chloro-4-nitrophenyl 2,3,4,6-tetra-O-acetyl-a-D-glucopyranoside

2-Chloro-4-nitrophenyl 2,3,4,6-tetra-O-acetyl-a-D-glucopyranoside

C20H22ClNO12 (503.083)


   

1-Decyl-3-Methylimidazolium Bis(Trifluoromethylsulfonyl)Imide

1-Decyl-3-Methylimidazolium Bis(Trifluoromethylsulfonyl)Imide

C16H27F6N3O4S2 (503.1347)


   
   

ent-Sitagliptin Phosphate

ent-Sitagliptin Phosphate

C16H16F6N5O5P (503.0793)


   

6-Aminohexyl-uridine-C1,5-diphosphate

6-Aminohexyl-uridine-C1,5-diphosphate

C15H27N3O12P2 (503.107)


   

6-O-malonylliquiritin

6-O-malonylliquiritin

C24H23O12- (503.1189)


   

[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] quinoxaline-2-carboxylate

[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] quinoxaline-2-carboxylate

C19H18N7O8P (503.0954)


   

(Pair of Enantiomers)

(Pair of Enantiomers)

C25H26ClNO6S (503.1169)


   

[7-Methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3,4,5-trihydroxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-ylidene]oxidanium

[7-Methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3,4,5-trihydroxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-ylidene]oxidanium

C24H23O12+ (503.1189)


   

(E)-7-[3-[(4-iodophenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid

(E)-7-[3-[(4-iodophenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid

C20H26INO4S (503.0627)


   

3-{3-[(2-bromo-4-chlorophenoxy)methyl]-4-methoxyphenyl}-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]acrylamide

3-{3-[(2-bromo-4-chlorophenoxy)methyl]-4-methoxyphenyl}-N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]acrylamide

C23H23BrClN3O3 (503.0611)


   

(indol-3-yl)acetyl-AMP

(indol-3-yl)acetyl-AMP

C20H20N6O8P- (503.108)


   

N-(2-fluorophenyl)-2-[3-(4-methoxyphenoxy)-4-oxo-2-(trifluoromethyl)chromen-7-yl]oxyacetamide

N-(2-fluorophenyl)-2-[3-(4-methoxyphenoxy)-4-oxo-2-(trifluoromethyl)chromen-7-yl]oxyacetamide

C25H17F4NO6 (503.0992)


   

Pyranodelphinin B

Pyranodelphinin B

C24H23O12+ (503.1189)


   

YH239-EE

YH239-EE

C25H27Cl2N3O4 (503.1379)


YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets in four AML cells (OCI-AML-3 and MOLM-13 with wt p53, NB4 with p53 mutation, and HL60 with p53 deletion).

   

(2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl)oxysulfonic acid

(2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl)oxysulfonic acid

C23H25N3O8S (503.1362)


   

(2s)-5-hydroxy-1-[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid

(2s)-5-hydroxy-1-[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid

C24H25NO11 (503.1428)


   

[8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-yl]oxidanesulfonic acid

[8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-yl]oxidanesulfonic acid

C26H21N3O6S (503.1151)


   

[(1e)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid

[(1e)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid

C23H25N3O8S (503.1362)


   

[(1z)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid

[(1z)-2-{2-[(3,4-dihydroxyphenyl)({4-[2-(dimethylamino)ethyl]imidazol-1-yl})methyl]-2h-1,3-benzodioxol-5-yl}ethenyl]oxysulfonic acid

C23H25N3O8S (503.1362)


   

5-hydroxy-1-[3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid

5-hydroxy-1-[3-(4-hydroxyphenyl)prop-2-enoyl]-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3-dihydroindole-2-carboxylic acid

C24H25NO11 (503.1428)


   

[1,4-bis(3,4-dihydroxyphenyl)-7,8-dihydroxy-2,5-dioxobenzo[e]indol-3-yl]acetic acid

[1,4-bis(3,4-dihydroxyphenyl)-7,8-dihydroxy-2,5-dioxobenzo[e]indol-3-yl]acetic acid

C26H17NO10 (503.0852)